DaVita HealthCare (DVA) Rises As Market Takes a Dip: Key Facts
Werte in diesem Artikel
In the latest trading session, DaVita HealthCare (DVA) closed at $152.69, marking a +0.77% move from the previous day. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow lost 0.42%, while the tech-heavy Nasdaq lost 1.89%.Shares of the kidney dialysis provider have depreciated by 4.13% over the course of the past month, outperforming the Medical sector's loss of 6.22% and lagging the S&P 500's loss of 1.7%.Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. The company is expected to report EPS of $2.21, up 18.18% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $3.25 billion, indicating a 3.47% increase compared to the same quarter of the previous year.Investors might also notice recent changes to analyst estimates for DaVita HealthCare. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare is currently a Zacks Rank #2 (Buy).In the context of valuation, DaVita HealthCare is at present trading with a Forward P/E ratio of 13.48. This indicates a discount in contrast to its industry's Forward P/E of 20.18.Meanwhile, DVA's PEG ratio is currently 0.74. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Outpatient and Home Healthcare industry held an average PEG ratio of 1.83.The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 87, which puts it in the top 35% of all 250+ industries.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow DVA in the coming trading sessions, be sure to utilize Zacks.com.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf DaVita HealthCare Partners
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DaVita HealthCare Partners
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu DaVita HealthCare Partners Inc
Analysen zu DaVita HealthCare Partners Inc
Datum | Rating | Analyst | |
---|---|---|---|
03.01.2019 | DaVita HealthCare Partners Buy | Deutsche Bank AG | |
14.12.2018 | DaVita HealthCare Partners Overweight | Barclays Capital | |
12.12.2017 | DaVita HealthCare Partners Outperform | Robert W. Baird & Co. Incorporated | |
08.11.2017 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
13.12.2016 | DaVita HealthCare Partners Neutral | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
03.01.2019 | DaVita HealthCare Partners Buy | Deutsche Bank AG | |
14.12.2018 | DaVita HealthCare Partners Overweight | Barclays Capital | |
12.12.2017 | DaVita HealthCare Partners Outperform | Robert W. Baird & Co. Incorporated | |
27.04.2015 | DaVita HealthCare Partners Outperform | Robert W. Baird & Co. Incorporated | |
18.10.2011 | DaVita outperform | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
08.11.2017 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
13.12.2016 | DaVita HealthCare Partners Neutral | Robert W. Baird & Co. Incorporated | |
04.11.2015 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
06.08.2015 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
13.03.2015 | DaVita HealthCare Partners Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DaVita HealthCare Partners Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen